Ayyan Investment Company

SASE:2140 Stock Report

Market Cap: ر.س1.4b

Ayyan Investment Past Earnings Performance

Past criteria checks 0/6

Ayyan Investment's earnings have been declining at an average annual rate of -76.3%, while the Healthcare industry saw earnings growing at 20.3% annually. Revenues have been growing at an average rate of 7.3% per year.

Key information

-76.3%

Earnings growth rate

-76.1%

EPS growth rate

Healthcare Industry Growth12.3%
Revenue growth rate7.3%
Return on equity-38.2%
Net Margin-64.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Ayyan Investment Company's (TADAWUL:2140) Business Is Trailing The Industry But Its Shares Aren't

Jul 18
Ayyan Investment Company's (TADAWUL:2140) Business Is Trailing The Industry But Its Shares Aren't

More Unpleasant Surprises Could Be In Store For Ayyan Investment Company's (TADAWUL:2140) Shares After Tumbling 29%

Apr 01
More Unpleasant Surprises Could Be In Store For Ayyan Investment Company's (TADAWUL:2140) Shares After Tumbling 29%

Ayyan Investment Company's (TADAWUL:2140) Business Is Trailing The Industry But Its Shares Aren't

Jan 19
Ayyan Investment Company's (TADAWUL:2140) Business Is Trailing The Industry But Its Shares Aren't

Can Ayyan Investment (TADAWUL:2140) Continue To Grow Its Returns On Capital?

Mar 15
Can Ayyan Investment (TADAWUL:2140) Continue To Grow Its Returns On Capital?

The Ayyan Investment (TADAWUL:2140) Share Price Has Gained 68% And Shareholders Are Hoping For More

Jan 30
The Ayyan Investment (TADAWUL:2140) Share Price Has Gained 68% And Shareholders Are Hoping For More

With EPS Growth And More, Ayyan Investment (TADAWUL:2140) Is Interesting

Jan 04
With EPS Growth And More, Ayyan Investment (TADAWUL:2140) Is Interesting

We're Not Counting On Ayyan Investment (TADAWUL:2140) To Sustain Its Statutory Profitability

Dec 08
We're Not Counting On Ayyan Investment (TADAWUL:2140) To Sustain Its Statutory Profitability

Revenue & Expenses Breakdown

How Ayyan Investment makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SASE:2140 Revenue, expenses and earnings (SAR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24330-2141210
30 Jun 24394-2321170
31 Mar 24364-2251230
31 Dec 23333-2161210
30 Sep 23296-174910
30 Jun 23270-134980
31 Mar 23260-105850
31 Dec 22266-45740
30 Sep 22270-22910
30 Jun 22268-2710
31 Mar 2227310730
31 Dec 212704750
30 Sep 2127310750
30 Jun 2127412770
31 Mar 2126516700
31 Dec 2025524660
30 Sep 2026019780
30 Jun 2025415760
31 Mar 2025113760
31 Dec 19246-1740
30 Sep 1923814610
30 Jun 1923513610
31 Mar 1923011580
31 Dec 182267590
30 Sep 18217-11600
30 Jun 18210-15590
31 Mar 18211-13600
31 Dec 17209-9600
30 Sep 17203-14570
30 Jun 17199-15570
31 Mar 17193-28560
31 Dec 16192-32560
30 Sep 16195-18550
30 Jun 16193-3530
31 Mar 1619145530
31 Dec 1515152430
30 Sep 1510326360
30 Jun 156134260
31 Mar 1516-5140
31 Dec 147-4130
30 Sep 1483360
30 Jun 14121560
31 Mar 14172170
31 Dec 13211670

Quality Earnings: 2140 is currently unprofitable.

Growing Profit Margin: 2140 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2140 is unprofitable, and losses have increased over the past 5 years at a rate of 76.3% per year.

Accelerating Growth: Unable to compare 2140's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2140 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (15.7%).


Return on Equity

High ROE: 2140 has a negative Return on Equity (-38.25%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies